Emily Graham - BC Bud Chief Officer
| BCBCF Stock | USD 0.05 0.01 10.61% |
Insider
Emily Graham is Chief Officer of The BC Bud
| Web | https://thebcbc.com |
BC Bud Management Efficiency
The company has return on total asset (ROA) of (0.1775) % which means that it has lost $0.1775 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3194) %, meaning that it generated substantial loss on money invested by shareholders. BC Bud's management efficiency ratios could be used to measure how well BC Bud manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Muthusamy RPh | ANI Pharmaceuticals | 56 | |
| Richard MD | Collegium Pharmaceutical | 64 | |
| Erica CPA | Biofrontera | 39 | |
| Eugene III | Biofrontera | 39 | |
| CCFP DipSportMed | Evolus Inc | 60 | |
| Matthew Coapman | cbdMD Inc | 48 | |
| Hermann Lubbert | Biofrontera | 68 | |
| OriMoni Mimon | INC Research Holdings | 36 | |
| Sibyl Swift | cbdMD Inc | 43 | |
| Rami Levy | INC Research Holdings | 59 | |
| Scott Sudduth | Collegium Pharmaceutical | N/A | |
| Amos Cohen | INC Research Holdings | 45 | |
| Jeff Holm | Biofrontera | N/A | |
| Sandra Beaver | Evolus Inc | 46 | |
| Thomas Flow | Akanda Corp | 46 | |
| Elizabeth JD | ANI Pharmaceuticals | N/A | |
| BCom BAcc | Akanda Corp | 44 | |
| John Weston | cbdMD Inc | N/A | |
| Marlo Manning | Collegium Pharmaceutical | N/A | |
| BComm BCom | Akanda Corp | 68 | |
| Raymond Coffman | cbdMD Inc | 62 | |
Management Performance
| Return On Equity | -0.32 | |||
| Return On Asset | -0.18 |
BC Bud Leadership Team
Elected by the shareholders, the BC Bud's board of directors comprises two types of representatives: BC Bud inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BCBCF. The board's role is to monitor BC Bud's management team and ensure that shareholders' interests are well served. BC Bud's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BC Bud's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Emily Graham, Chief Officer | ||
| Thomas Taylor, Pres Director | ||
| Daniel SouthanDwyer, Creative Devel | ||
| Brayden Sutton, Chairman CEO |
BCBCF Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is BC Bud a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.32 | |||
| Return On Asset | -0.18 | |||
| Profit Margin | (1.96) % | |||
| Operating Margin | (1.82) % | |||
| Current Valuation | 1.82 M | |||
| Shares Outstanding | 53.02 M | |||
| Shares Owned By Insiders | 66.39 % | |||
| Price To Book | 3.14 X | |||
| Price To Sales | 4.63 X | |||
| Revenue | 151 |
Currently Active Assets on Macroaxis
Other Information on Investing in BCBCF Pink Sheet
BC Bud financial ratios help investors to determine whether BCBCF Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BCBCF with respect to the benefits of owning BC Bud security.